Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs e l f Beauty Inc (ELF) Price & Performance

Abbott LaboratoriesTrade
e l f Beauty IncTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs e l f Beauty Inc — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while e l f Beauty Inc trades at $94.99 (market cap $5.62B). The key difference: Abbott Laboratories is far larger — about 33.4× e l f Beauty Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.

ABTELF
Market Cap
$187.95B$5.62B
Sector
HealthTechnology
52-Week High
$136.62$146.67
52-Week Low
$82.57$49.57
Enterprise Value
$214.96B$6.20B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

e l f Beauty Inc

ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.

Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About e l f Beauty Inc

e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.

Read more on ELF